Literature DB >> 31212316

A Systematic Review and Meta-analysis of Randomized Controlled Trials on the Effects of Turmeric and Curcuminoids on Blood Lipids in Adults with Metabolic Diseases.

Fen Yuan1, Hui Dong1, Jing Gong1, Dingkun Wang1, Meilin Hu1, Wenya Huang1, Ke Fang1, Xin Qin1, Xin Qiu1, Xueping Yang1, Fuer Lu1.   

Abstract

Dyslipidemia is a global health problem and a high risk factor for atherosclerosis, which can lead to serious cardiovascular disease (CVD). Existing studies have shown inconsistent effects of turmeric and curcuminoids on blood lipids in adults. We performed this systematic review and meta-analysis to evaluate the effects of turmeric and curcuminoids on blood triglycerides (TG), total cholesterol (TC), LDL cholesterol, and HDL cholesterol. We searched the English databases of the Web of Science, PubMed, Ovid (including EMBASE and MEDLINE), Scopus, and the Cochrane Library and 2 Chinese databases, Wanfang Data and China National Knowledge Infrastructure, for randomized controlled trials (RCTs) that studied the effects of turmeric and curcuminoids on blood TG, TC, LDL cholesterol, and HDL cholesterol in subjects with metabolic diseases. With random-effects models, separate meta-analyses were conducted by using inverse-variance. The results are presented as the mean difference with 95% CIs. Evidence from 12 RCTs for TG, 14 RCTs for TC, 13 RCTs for LDL cholesterol, and 16 RCTs for HDL cholesterol showed that turmeric and curcuminoids could lower blood TG by -19.1 mg/dL (95% CI: -31.7, -6.46 mg/dL; P = 0.003), TC by -11.4 mg/dL (95% CI: -17.1, -5.74 mg/dL; P < 0.0001), and LDL cholesterol by -9.83 mg/dL (95% CI: -15.9, -3.74 mg/dL; P = 0.002), and increase HDL cholesterol by 1.9 mg/dL (95% CI: 0.31, 3.49 mg/dL; P = 0.02). In conclusion, turmeric and curcuminoids can significantly modulate blood lipids in adults with metabolic diseases. However, these findings should be interpreted cautiously because of the significant heterogeneity between included studies (I2 > 50%). There is a need for further RCTs in future.
Copyright © American Society for Nutrition 2019.

Entities:  

Keywords:  HDL cholesterol; LDL cholesterol; curcuminoids; lipids; total cholesterol; triglyceride; turmeric

Mesh:

Substances:

Year:  2019        PMID: 31212316      PMCID: PMC6743846          DOI: 10.1093/advances/nmz021

Source DB:  PubMed          Journal:  Adv Nutr        ISSN: 2161-8313            Impact factor:   8.701


  54 in total

1.  Curcuminoids for the management of hypertriglyceridaemia.

Authors:  Amirhossein Sahebkar
Journal:  Nat Rev Cardiol       Date:  2014-01-07       Impact factor: 32.419

2.  Treatment of Non-alcoholic Fatty Liver Disease with Curcumin: A Randomized Placebo-controlled Trial.

Authors:  Sepideh Rahmani; Sedigheh Asgary; Gholamreza Askari; Mahtab Keshvari; Mahdi Hatamipour; Awat Feizi; Amirhossein Sahebkar
Journal:  Phytother Res       Date:  2016-06-08       Impact factor: 5.878

3.  Efficacy of turmeric (curcumin) in pain and postoperative fatigue after laparoscopic cholecystectomy: a double-blind, randomized placebo-controlled study.

Authors:  Krishna Adit Agarwal; C D Tripathi; Brij B Agarwal; Satish Saluja
Journal:  Surg Endosc       Date:  2011-06-14       Impact factor: 4.584

4.  Prevalence of dyslipidemia and metabolic syndrome risk factor in overweight and obese children.

Authors:  Patricia L Casavalle; Fima Lifshitz; Laura S Romano; Marcela Pandolfo; Anabella Caamaño; Patricia M Boyer; Patricia N Rodríguez; Silvia M Friedman
Journal:  Pediatr Endocrinol Rev       Date:  2014-12

5.  Effects of supplementation with curcuminoids on dyslipidemia in obese patients: a randomized crossover trial.

Authors:  Akram Mohammadi; Amirhossein Sahebkar; Mehrdad Iranshahi; Maral Amini; Roshanak Khojasteh; Majid Ghayour-Mobarhan; Gordon A Ferns
Journal:  Phytother Res       Date:  2012-05-21       Impact factor: 5.878

6.  Interleukin-6-deficient mice develop mature-onset obesity.

Authors:  Ville Wallenius; Kristina Wallenius; Bo Ahrén; Mats Rudling; Hans Carlsten; Suzanne L Dickson; Claes Ohlsson; John-Olov Jansson
Journal:  Nat Med       Date:  2002-01       Impact factor: 53.440

Review 7.  Recent advances in pharmacotherapy for hypertriglyceridemia.

Authors:  Amirhossein Sahebkar; Gerard T Chew; Gerald F Watts
Journal:  Prog Lipid Res       Date:  2014-07-30       Impact factor: 16.195

Review 8.  Management of dyslipidemia as a cardiovascular risk factor in individuals with nonalcoholic fatty liver disease.

Authors:  Kathleen E Corey; Naga Chalasani
Journal:  Clin Gastroenterol Hepatol       Date:  2013-08-17       Impact factor: 11.382

9.  Curcumin inhibits imiquimod-induced psoriasis-like inflammation by inhibiting IL-1beta and IL-6 production in mice.

Authors:  Jun Sun; Yi Zhao; Jinhong Hu
Journal:  PLoS One       Date:  2013-06-25       Impact factor: 3.240

Review 10.  Efficacy and safety of turmeric and curcumin in lowering blood lipid levels in patients with cardiovascular risk factors: a meta-analysis of randomized controlled trials.

Authors:  Si Qin; Lifan Huang; Jiaojiao Gong; Shasha Shen; Juan Huang; Hong Ren; Huaidong Hu
Journal:  Nutr J       Date:  2017-10-11       Impact factor: 3.271

View more
  4 in total

Review 1.  The effect of statin therapy in combination with ezetimibe on circulating C-reactive protein levels: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Seyyed Mostafa Arabi; Mahla Chambari; Mahsa Malek-Ahmadi; Leila Sadat Bahrami; Vahid Hadi; Manfredi Rizzo; Amirhossein Sahebkar
Journal:  Inflammopharmacology       Date:  2022-08-21       Impact factor: 5.093

Review 2.  Curcuminoids for Metabolic Syndrome: Meta-Analysis Evidences Toward Personalized Prevention and Treatment Management.

Authors:  Agustina Dwi Retno Nurcahyanti; Fonny Cokro; Martha P Wulanjati; Mona F Mahmoud; Michael Wink; Mansour Sobeh
Journal:  Front Nutr       Date:  2022-06-09

Review 3.  Curcumin - The Nutraceutical With Pleiotropic Effects? Which Cardiometabolic Subjects Might Benefit the Most?

Authors:  Stanisław Surma; Amirhossein Sahebkar; Jakub Urbański; Peter E Penson; Maciej Banach
Journal:  Front Nutr       Date:  2022-05-17

Review 4.  Role of Biomarkers in FLT3 AML.

Authors:  Jiao Wei; Ai-Min Hui
Journal:  Cancers (Basel)       Date:  2022-02-24       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.